02 August 2018
- Study to randomize 420 patients in clinical sites across the U.S.
- Top-line results expected H2 2019
- Targets $5 billion worldwide glaucoma market1
Sophia Antipolis, France / Research Triangle Park, NC, United States
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the initiation of a Phase 2 clinical study evaluating NCX 470,